Magnetic tweezers were employed to investigate the interactions between DNA and cisplatin (transplatin). Cisplatin shortened DNA and reduced its persistence length more significantly than transplatin due to the formation of many more diadducts than those formed by transplatin. Interestingly, the presence of transplatin could enhance the ability of cisplatin in shortening DNA. An optimal concentration ratio of transplatin to cisplatin existed at which cisplatin showed the highest ability in shortening DNA. Moreover, abrupt length changes were also observed when DNA was treated with a mixture of cisplatin and transplatin at high concentrations. A model was proposed to qualitatively explain well these results.
I. INTRODUCTION
Cisplatin has been widely used in cancer chemotherapy for more than four decades [1] . Intensive research work has been carried out to investigate the mechanism for the biological effect of cisplatin [2] [3] [4] [5] . It is generally accepted that the major pharmacological target of cisplatin is DNA [6] and its therapeutic activity is attributed to the final formation of DNA cross-links, mainly including intrastrand cross-links between neighboring purine bases [65% 1,2-d(GpG), 25% 1,2-d(ApG), 5-10% 1,3-d(GpNpG)] and interstrand adducts [7] [8] [9] [10] . Cisplatin is highly effective in treating various malignancies, while transplatin, the geometric isomer of cisplatin, is clinically ineffective due to its distinct spatial arrangement of ligands to DNA [11] [12] [13] . Transplatin cannot form cross-links between neighboring bases because of a structure restriction [14, 15] but can form 1,3-intrastrand and interstrand cross-links [16, 17] . Cisplatin binds kinetically to DNA in three steps: (a) chloride ligand hydrolysis; (b) aquated cisplatin binding to a guanine base to form a monoadduct with a half-time of about 5 min; and (c) diadduct formation by 1,2-instrastrand crosslinking adjacent guanine bases [11, 18] . Transplatin binds DNA to form monoadducts with a rate similar to cisplatin, but forms diadducts much more slowly than cisplatin [19] .
Despite extensive research on cisplatin and transplatin, investigations of DNA binding activities of platinum drugs are needed to understand these drugs' biophysical characteristics. In the past few years, theoretical studies have been carried out on cisplatin's reaction with DNA by using computational methods [20] [21] [22] [23] [24] . In addition, single-molecule techniques have been widely used to investigate the DNA structure in an overstretching region [25, 26] , the interactions between DNA and protein [27] [28] [29] , and, especially in recent years, between DNA and drugs. For example, Gaub's group studied the structural transition of DNA due to cisplatin binding [30] . Lee et al. employed magnetic tweezers to measure the effect of cisplatin on the persistence lengths of kinked DNA at high and low tensions [31] . In our previous paper, the condensation of DNA was investigated by employing atomic force microscopy (AFM) and magnetic tweezers, and a softening-looping-* pywang@aphy.iphy.ac.cn shortening-condensing model was proposed to explain the DNA condensation phenomenon [32] .
Direct measurements of the interactions between DNA and platinum drugs can show the dynamics of DNA binding and reveal directly the efficacy of these drugs. In this paper, we employed magnetic tweezers to investigate the elastic response of single DNA molecules induced by a combination of cisplatin and transplatin. The experimental data showed that cisplatin effectively decreased the persistence length of DNA and even caused DNA condensing at high concentrations. Interestingly, in comparison with cisplatin, a mixture of cisplatin and transplatin had an enhanced ability to shorten DNA at low transplatin concentrations, while it had a compromised ability at high transplatin concentrations. In addition, abrupt length decreases were observed that corresponded to interstrand cross-links formed by cisplatin-transplatin mixture.
II. EXPERIMENT
Our magnetic tweezers were purchased from Pico Twist Company (France), and the standard use of magnetic tweezers and the protocol for building magnetic tweezers followed the general procedure as described by Croquette and co-workers [33] [34] [35] . In brief, a lambda DNA molecule was bound at one end to a glass coverslip via the bonds between digoxigenin and antidigoxigenin and to a magnetic Dynabead (Invitrogen Norway) at the other end via biochemical reactions between biotin and streptavidin [36] , as shown in Fig. 1(a) . Two small NdFeB-controlled magnets were used to pull on the Dynabead and thus stretch the DNA molecule. The realtime bead position was observed via a microscope objective (Olympus 100 × 1.2, oil immersion) and the sample image was projected onto a JAI Giga-Ethernet CCD camera. The algorithm for tracking the bead position offered remarkable accuracy [33] , with the measurement uncertainty being typically approximately 1 nm in the x, y, and z directions. The experimental noise was mainly from the Brownian motion of the bead attached to DNA. Figure 1(b) shows the structure of the flow cell. A thoroughly cleaned coverslip was silanized with Sigmacote (Sigma-Aldrich) and rinsed with distilled de-ionized water (ddH 2 O). A channel (50 × 5 mm 2 ) was cut into 130-μm-thick double-sided tape (3M Corporation). The double-sided tape was sandwiched between the glass coverslip and Mylar film and a 15-μl flow cell was thus formed. We injected antidigoxigenin (10 mg/ml Roche) into the flow cell for overnight at 37
• C. To eliminate the unbound antidigoxigenin, a passivation buffer [10-mg/ml bovine serum albumin (BSA), 1-mM ethylenediamine tetra-acetic acid (EDTA), 10-mM pH 7.4 phosphate buffer, 10-mg/ml Pluronic F127 surfactant (Sigma-Aldrich), 3-mM NaN 3 ] was injected in the flow cell for overnight at 37
• C. To anchor the DNA-bead complex to the glass coverslip coated with antidigoxigenin, a 2-μl DNA-bead mixture was injected into the flow cell for 15 min. As a final step, the flow cell was rinsed with a 1-ml 4-(2-hydroxyl)piperazine-1-ethanesulphonic acid (HEPES) buffer (10-mM HEPES, 30-mM CH 3 COONa) to eliminate the magnetic beads that were nonspecifically bound to the surface.
To investigate the effect of platinum drugs on DNA, our single-molecule experiments were carried out in the following way. (a) First, we recorded the bead's calibration images which stored the information about the bead at various distances from the focal point of the objective. (b) Next, while stretching the lambda DNA with a large force (about 5 pN), platinum drugs of a given concentration were injected into the flow cell and incubated for 15 min. (c) To check the dynamical process of platinum drugs changing from monoadducts to diadducts with DNA, the flow cell was rinsed with a HEPES buffer to eliminate the cisplatin (transplatin) unbound to DNA. (d) Finally, we stretched the DNA with a small force and recorded the z position of the bead. The half-life of a streptavidin-biotin bond under a force of 1 pN is expected to be around 10 s [37, 38] . To show the dynamics of the interaction between DNA and cisplatin (transplatin) for hours, we exerted a relatively small force of ∼0.5 pN on the bead in the process of the interaction between DNA and drugs. Before a real measurement with magnetic tweezers, we needed to test whether the bead was bound to the surface by a single DNA molecule. So we pulled the bead with a large force (about 5 pN) and rotated the magnets by ∼100 turns. If the bead was tethered by more than one DNA molecule, the distance between the bead and the glass coverslip would decrease dramatically. We tracked at least five beads at the same time in every experiment, and the length change of those DNA molecules that were well linked to the glass coverslip for hours showed a complete process of interaction between DNA and drugs. Those stable experimental results were chosen for analysis without any bias.
III. RESULTS
The persistence length, which characterizes the flexibility of DNA, is a basic mechanical parameter for single DNA molecules. The elasticity of a single DNA molecule is well described by the wormlike-chain (WLC) model [36, 39, 40] . The persistence length and contour length of a DNA are obtained by fitting the force-extension curves with the following equation [41] :
with a 2 = −0.516 422 8, a 3 = −2.737 418, a 4 = 16.074 97, a 5 = −38.876 07, a 6 = 39.499 44, and a 7 = −14.177 18. Here l 0 denotes the molecular contour length (l 0 = 16.4 μm for lambda DNA) and ξ the persistence length of DNA, which is around 50 nm under physiological salt conditions [36, 42] . It has been generally believed that base stacking plays an important role in the persistence length of DNA [43] and proteins or drugs binding to DNA will change the persistence length of DNA [44] .To investigate the effects of cisplatin and transplatin on the elastic property of DNA, we measured the elastic response of the lambda DNA treated with low concentrations of the compounds. First we treated DNA with 50-μM cisplatin for about 2 h and then measured the elastic response. As shown in Fig. 2(a) , the experiment data can be well fitted with the WLC model, giving l 0 = 16.8 ± 0.05 μm and ξ = 25 ± 2.6 nm. To investigate the difference in the effects of cisplatin and transplatin on the elastic response of DNA, we carried out a series of measurements, as above, for DNA treated with the drugs for different times, from which the persistence length of DNA as a function of treatment time was obtained. As shown in Fig. 2(b) , both cisplatin and transplatin reduced the persistence length of DNA with increasing treatment time. The effect of cisplatin on decreasing the persistence length of DNA was more significant than that of transplatin, which was consistent with the different mechanisms for the two drugs to interact with DNA. Though both cisplatin and transplatin could form monoadducts with DNA, cisplatin could bind DNA to form many more diadducts. Structural studies by using x-ray crystallography showed that a 1,2-d(GpG) cross-link formed with DNA-induced bending of the double helix by 35
• -49
• toward the major groove and a local duplex unwinding of about 25
• [45] . The structural data revealed that the destacking of the bases induced the decrease of the persistence length. With more diadducts formed, the base stacking energy was weakened more and the persistence length decreased more due to more stored length in the kinks formed by these diadducts. Since transplatin formed many less diadducts than cisplatin and the monoadducts changed the DNA structure much less than the diadducts, it was expected that transplatin could not reduce the base stacking energy as much as cisplatin and, thus, the persistence length changed by transplatin was less than cisplatin.
The adduct formation process from mono-to diadduct with DNA is crucial to the bending and unwinding of DNA and is ultimately responsible for the anticancer activity of cisplatin. The difference in the anticancer activity of cisplatin and transplatin was studied quantitatively. After the two ends of a lambda DNA were anchored to the glass coverslip and magnetic bead, respectively, the flow cell was rinsed with 200-μl HEPES buffer to eliminate the effects of chlorine ions on the drug's binding to DNA. We injected cisplatin (transplatin) into the flow cell and recorded the DNA length in the process of cisplatin (transplatin) binding to DNA. The length changes of DNA treated with different cisplatin (transplatin) concentrations were recorded, as shown in Figs. 3(a) and 3(c) . Since it usually takes a long time for cisplatin and transplatin to bind DNA and completely form diadducts, we recorded the length change of DNA up to about 20 h. We found that in the first hour cisplatin and transplatin shortened DNA relatively fast and the DNA was shortened by more than 60% of the final DNA length. From the recorded length changes in the first hour, we can obtain the decreasing speeds of the length and final length changes, the two parameters that can reflect two important aspects of drug activities. In this paper, the experimental data of the first hour are chosen to clearly show the relatively fast process.
When DNA was treated with a relatively low concentration of cisplatin (50 and 200 μM), the length change can be described by a single-exponential decay, L = L 0 e (−λt) + c, where c is a constant. When DNA was treated with a relatively high concentration of cisplatin (500 and 1000 μM), the length change cannot be fitted well by a single-exponential decay, which can be explained as follows. DNA shortened in length when treated with cisplatin due to cisplatin crosslinking purine bases to form diadducts. Many previous works showed that cisplatin formed about 90% intrastrand cross-links between neighboring purine bases [11] . When DNA was treated with a low concentration of cisplatin, the interaction between DNA and cisplatin was predominated by one dynamical process of 1,2-intrastrand cross-link forming, which can be described by a single-exponential decay. As the cisplatin concentration was increased, the DNA shortening speed was increased and the dynamical processes of 1,3-intrastrand cross-links and interstrand adducts forming beside the formation of 1,2-intrastrand cross-links were introduced.
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The curve fitting of this multiple dynamical processes by a single-exponential decay gives a mean decay speed that can distinguish between the different activities of drugs for different concentrations. At the same time, the final DNA length L final became shorter while DNA was treated with a higher concentration of cisplatin, implying more diadducts were formed.
The decay constant λ and final DNA length change L final as functions of drug concentration are shown in Figs. 3(b)  and 3(d) . For cisplatin, the decay constant λ increased with increasing drug concentration and would at last become saturated. This feature could be interpreted as follows. The number of drug binding locations on lambda DNA was fixed and a higher concentration of cisplatin induced a larger amount of cisplatin bound to DNA and, after all drug binding locations were occupied, the amount of cisplatin bound to DNA became saturated. For transplatin, the DNA length decreased more quickly with a higher transplatin concentration. However, both the decreasing speed and total length change were much less than those for the case of cisplatin. The different decay speeds for cisplatin [ Fig. 3(b) ] and transplatin [ Fig. 3(d) ] revealed their different abilities to form diadducts with DNA. Due to the structure limitation, transplatin formed many less diadducts than cisplatin.
As mentioned above, the persistence length of DNA is decreased by transplatin due mainly to the formation of monoadducts and a small amount of diadducts with DNA, while the decrease is more significant for cisplatin due to many more diadducts formed by cisplatin with DNA. If DNA is treated with a mixture of cisplatin and transplatin, transplatin and cisplatin will compete in the process of monoadduct formation. To have more insight into the effect of this competition, a series of experiments were carried out, with the DNA being treated with mixtures of cisplatin and transplatin of different concentration ratios.
In Fig. 4(a) , the length change of DNA is shown when DNA was treated with 500-μM cisplatin and different concentrations of transplatin. The experimental data showed that transplatin enhanced the ability of cisplatin to shorten DNA at low concentrations (200 and 300 μM), but reduced the ability at high concentrations (600, 700, and 800 μM). The fitted single-exponential decay constants and the final DNA length change L final versus transplatin concentration for a fixed cisplatin concentration are shown in Fig. 4(b) . It was seen that, for the fixed 500-μM cisplatin, the transplatin had an optimum concentration (200 μM) at which the efficiency of DNA shortening had the largest value. We carried out a similar measurement for the mixture of transplatin at different concentrations and 200 μM/600 μM cisplatin, respectively, and the experimental data showed similar results (data not shown here). Previous experiments showed that both cisplatin and transplatin had two effects on DNA: (1) binding to purine bases permanently to reduce the DNA persistence length more significantly, and (2) shortening DNA while diadducts were formed. Since transplatin formed many less diadducts with DNA than cisplatin, it would compete with cisplatin in forming monoadducts. At a low transplatin concentration the mixture of cisplatin and transplatin would reduce the DNA persistence length more significantly than cisplatin alone of the same concentration. The smaller persistence length helped cisplatin form more diadducts, resulting in a higher efficacy for the mixture. At a high transplatin concentration, transplatin competed with cisplatin in forming monoadducts, resulting in less cisplatin molecules bound to DNA and a lower efficacy for the mixture.
The different diadducts formed by cisplatin and transplatin with DNA have been studied extensively [15, [46] [47] [48] . The diadducts formed by cisplatin with DNA include 1,2-intrastrand, 1,3-intrastrand, and interstrand cross-links, while diadducts formed by transplatin including 1,3-intrastrand and interstrand cross-links are much less than those formed by cisplatin. In our single-molecule experiment, the different effects of the two drugs indicated their different abilities in softening and condensing DNA. When DNA is treated with a mixture of cisplatin and transplatin, it is expected that, when the transplatin concentration is high and is higher than the cisplatin concentration, the 1,2-intrastrand cross-links will be significantly restrained. Now if the cisplatin concentration is low, the persistence length of DNA is not as small due to few cisplatin molecules bound to the DNA that the transplatin can rarely form 1,3-intrastrand and interstrand cross-links. What happens if the cisplatin concentration is high? Interestingly, abrupt length drops occurred during the DNA shortening process [ Fig. 5(a) ] when DNA was treated with a mixture of 500-μM cisplatin and 900-μM transplatin. We repeated the experiments and always obtained similar results. The statistical distribution of the step size was wide [ Fig. 5(b) ], indicating that the stepping process was rather random. The stepwise shortening was rarely observed when DNA was treated with a mixture with a low concentration of cisplatin or with a concentration of transplatin that was less than that of cisplatin. The step sizes are huge and each one corresponds to the condensation of one segment of DNA due to the interstrand cross-links.
IV. DISCUSSION
In the present paper, magnetic tweezers were employed to measure directly the distortion of DNA due to the binding of cisplatin and transplatin. Cisplatin and transplatin bind DNA to form monoadducts and then diadducts. This process is crucial to the efficacy of the drugs. Transplatin binds DNA to form diadducts much more slowly than cisplatin. The difference in the rates of forming diadducts explains the different biological activities of the two compounds [11] . Our single-molecule experiment directly showed the difference in the interaction and formation processes of cisplatin and transplatin with DNA changing from mono-to diadducts.
The DNA length change revealed the structure distortion of DNA caused by drug binding. For cisplatin, DNA was shortened with an exponential decay, and the decay rate increased with increasing drug concentration [Figs. 3(a) and 3(b)]. A higher concentration of cisplatin induced more adduct formation with DNA. The change in DNA persistence length with time revealed the effect of cisplatin on the elastic response of DNA. During the process from mono-to diadduct formation, cisplatin increasingly reduced the DNA persistence length and then the cisplatin-DNA complex arrived at the final steady state. In comparison with cisplatin, transplatin bounded to DNA in a similar scenario, but the biological activity of transplatin was much lower than cisplatin [Figs. 3(c) and 3(d)]. At a given drug concentration, the shortening of DNA treated with transplatin was much slower than that treated with cisplatin. In addition, the effect of transplatin on DNA persistence length was also less than that of cisplatin. These results demonstrated clearly the different biological activities of cisplatin and transplatin at the single-molecule level.
The effect of a mixture of cisplatin and transplatin on drug efficiency in cross-linking DNA was studied. In comparison with cisplatin alone, the efficiency of DNA shortening by the mixture was enhanced at a low transplatin concentration and reduced at a high transplatin concentration. For a fixed concentration of cisplatin (500 μM), an optimum concentration of the transplatin (200 μM) existed at which the efficiency of DNA shortening had the largest value (Fig. 4) . These results implied that the clinically ineffective transplatin could enhance the efficacy of cisplatin in cancer chemotherapy. More interestingly, under high concentrations of cisplatin and transplatin, stepwise DNA shortening was observed when the concentration of transplatin was higher than that of cisplatin (Fig. 5) .
The results could be interpreted by our proposed model as shown in Fig. 6 . In Fig. 6(a) , the relative concentration of transplatin is low and the transplatin bindings to DNA to form monoadducts reduce the DNA persistence length, which facilitates cisplatin to form diadducts of intrastrand cross-links with DNA. Thus the biological activity of the mixture of cisplatin and transplatin is higher than cisplatin alone. In Fig. 6(b) , the relative concentration of transplatin is intermediate, and transplatin competed with cisplatin in the formation of monoadducts with DNA, impairing the efficacy of cisplatin to form diadducts of intrastrand cross-links with DNA. Thus, the biological activity of the mixture becomes lower than with cisplatin alone. In Fig. 6(c) , when the concentrations of both compounds are high and the concentration of transplatin is higher than cisplatin, the binding of transplatin to DNA inhibits seriously the bound cisplatin to form diadducts of intrastrand cross-links with DNA. Thus the efficiency of the mixture in shortening DNA is significantly restrained. However, since the cisplatin of a high concentration reduces the DNA persistence length more significantly, the transplatin becomes prone to form interstrand cross-links, helping more DNA to be linked immediately via interstrand cross-linking by cisplatin or transplatin. This local DNA condensation due to interstrand cross-linking by drugs results in abrupt changes in DNA length, as observed in our single-molecule experiment.
We had investigated the interactions between cisplatin (transplatin) and DNA at the single DNA molecule level. The dynamic processes of DNA binding of the two compounds to form diadducts were studied. Because of the different DNA binding characteristics of the two compounds, their effects on the DNA structure in terms of DNA shortening speed as well as persistence length change were quite different, correlating with the different biological activities of the two drugs. Depending on the concentration of transplatin, the presence of transplatin might enhance or reduce the efficacy of cisplatin in modifying DNA structures. For a fixed concentration of cisplatin, an optimum concentration of the transplatin existed at which the efficiency of DNA shortening had the largest value. Moreover, under high concentrations of cisplatin and transplatin, stepwise DNA shortening was observed when the concentration of transplatin was higher than that of cisplatin. A model was proposed that could explain well the results.
